The 12 closest competitors and alternatives to BOTANIX PHARMACEUTICALS LTD among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what BOTANIX PHARMACEUTICALS LTD actually does, not by market-cap band.
Subscribe to see BOTANIX PHARMACEUTICALS LTD’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Botanix Pharmaceuticals Ltd. is a dermatology company focused on developing pharmaceutical products and treatments. The company is headquartered in West Perth, Western Australia, and operates within the Australian life sciences market.
BOTANIX PHARMACEUTICALS LTD is a pharmaceuticals, biotechnology & life sciences company headquartered in Melbourne, Australia. Its most recent funding round raised $20M in July 2019. Xcout tracks 17 named people at BOTANIX PHARMACEUTICALS LTD, including Andrew Kang (Chief Executive Officer).
11 more named people on record for BOTANIX PHARMACEUTICALS LTD, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $20M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Ranked by semantic similarity — how close each company is to BOTANIX PHARMACEUTICALS LTD by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
Pharmaceuticals
Burke Therapeutics, LLC is a pharmaceutical company that markets prescription and over-the-counter products to physicians and pharmacies nationwide. The company also develops early-stage drug candidates specifically designed for patients suffering from dermatological conditions with limited current treatments.
Pharmaceuticals
Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company is the creation of non-surgical solutions specifically targeting dermatological malignancies.
Similar pharmaceuticals, biotechnology & life sciences company
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Pharmaceuticals
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Similar pharmaceuticals, biotechnology & life sciences company
Tryptamine Therapeutics Limited is a public pharmaceuticals, biotechnology, and life sciences company based in Australia, trading under the ticker TYP.
Similar pharmaceuticals, biotechnology & life sciences company
AFT Pharmaceuticals Limited engages in the complete lifecycle of pharmaceutical products, from their initial development and licensing to their distribution and ultimate sale. The company's reach extends throughout New Zealand, Australia, Asia, and various other international markets. Its extensive product range encompasses treatments for allergies, cold and flu symptoms, ophthalmic conditions, first aid, pain management, digestive health, dermatological concerns, and medicated vitamin supplements. Established in 1997, AFT Pharmaceuticals has its corporate headquarters situated in Auckland, New Zealand.
Similar pharmaceuticals, biotechnology & life sciences company
Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Pharmaceuticals
Telix Pharmaceuticals is a commercial-stage biopharmaceutical company headquartered in Melbourne, Australia, focused on the development of diagnostic and therapeutic radiopharmaceuticals.
Similar pharmaceuticals, biotechnology & life sciences company
ECS Botanics Holdings Ltd specializes in the cultivation, processing, and commercialization of medicinal cannabis products. The enterprise also markets a variety of hemp-derived wellness and food items and is active in the agricultural sector. Its primary operations are headquartered in Launceston, Australia.
Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Search any company we track to see its competitive set.
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
Funding, investors, tech stack, hiring signals, leadership and corporate events — for BOTANIX PHARMACEUTICALS LTDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →